| Year |
Citation |
Score |
| 2006 |
Ewens A, Luo L, Berleth E, Alderfer J, Wollman R, Hafeez BB, Kanter P, Mihich E, Ehrke MJ. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Research. 66: 5419-26. PMID 16707470 DOI: 10.1158/0008-5472.Can-05-3963 |
0.359 |
|
| 2003 |
Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth ES. Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunology, Immunotherapy : Cii. 52: 463-72. PMID 12698271 DOI: 10.1007/S00262-003-0391-X |
0.379 |
|
| 2001 |
Berleth ES, Masso-Welch PA, Kazim LA, Ip MM, Mihich E, Ehrke MJ. Expression, tissue distribution, and cellular localization of the antiapoptotic TIP-B1 protein. Journal of Leukocyte Biology. 69: 995-1005. PMID 11404387 DOI: 10.1189/Jlb.69.6.995 |
0.595 |
|
| 2001 |
Henn AD, Berleth ES, Mihich E, Ehrke MJ. Changes in cytosolic and membrane TNF inhibitory protein-B1 (TIP-B1) levels associated with protection from TNF-induced cytotoxicity. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 15: 1315-7. PMID 11344125 DOI: 10.1096/Fj.00-0543Fje |
0.666 |
|
| 2001 |
Mihich E, Berleth E, Henn A, Ehrke M. Modulation of tumor necrosis factor (TNFα) in cancer therapeutics European Journal of Cancer. 37: S148. DOI: 10.1016/S0959-8049(01)81037-6 |
0.599 |
|
| 2000 |
Berleth ES, Henn AD, Gurtoo HL, Wollman R, Alderfer JL, Mihich E, Ehrke MJ. A novel tumor necrosis factor-alpha inhibitory protein, TIP-B1. International Journal of Immunopharmacology. 22: 1137-42. PMID 11137621 DOI: 10.1016/S0192-0561(00)00071-0 |
0.684 |
|
| 2000 |
Ehrke MJ, Verstovsek S, Maccubbin DL, Ujházy P, Zaleskis G, Berleth E, Mihich E. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. International Journal of Cancer. 87: 101-9. PMID 10861459 DOI: 10.1002/1097-0215(20000701)87:1<101::Aid-Ijc15>3.0.Co;2-B |
0.433 |
|
| 1999 |
Nadadur SS, Ehrke MJ, Gurtoo HL. A novel TNF-inducible message with putative growth suppressor function. Biochimica Et Biophysica Acta. 1489: 433-9. PMID 10673047 DOI: 10.1016/S0167-4781(99)00189-X |
0.396 |
|
| 1999 |
Berleth ES, Nadadur S, Henn AD, Eppolito C, Shiojiri S, Gurtoo HL, Ehrke MJ, Mihich E. Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis. Cancer Research. 59: 5497-506. PMID 10554026 |
0.7 |
|
| 1998 |
Ehrke MJ, Verstovsek S, Pocchiari SK, Krawczyk CM, Ujházy P, Zaleskis G, Maccubbin DL, Meer JM, Mihich E. Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. International Journal of Cancer. 76: 579-86. PMID 9590137 DOI: 10.1002/(Sici)1097-0215(19980518)76:4<579::Aid-Ijc22>3.0.Co;2-1 |
0.375 |
|
| 1996 |
Ujházy P, Berleth ES, Pietkiewicz JM, Kitano H, Skaar JR, Ehrke MJ, Mihich E. Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. International Journal of Cancer. 68: 493-500. PMID 8945621 DOI: 10.1002/(Sici)1097-0215(19961115)68:4<493::Aid-Ijc15>3.0.Co;2-6 |
0.326 |
|
| 1995 |
Krawczyk CM, Verstovsek S, Ujházy P, Maccubbin D, Ehrke MJ. Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunology, Immunotherapy : Cii. 40: 347-57. PMID 7627991 DOI: 10.1007/Bf01525385 |
0.422 |
|
| 1995 |
Ehrke MJ, Verstovsek S, Krawczyk CM, Ujházy P, Zaleskis G, Maccubbin DL, Mihich E. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. International Journal of Cancer. 63: 463-71. PMID 7591249 DOI: 10.1002/Ijc.2910630327 |
0.344 |
|
| 1994 |
Tzai TS, Huben RP, Zaleskis G, Berleth ES, Ehrke MJ, Mihich E. Effect of perioperative chemoimmunotherapy with cyclophosphamide and autologous tumor vaccine in murine MBT-2 bladder cancer. The Journal of Urology. 151: 1680-6. PMID 8189597 DOI: 10.1016/S0022-5347(17)35344-2 |
0.392 |
|
| 1994 |
Ujházy P, Klobusická M, Babusíková O, Strausbauch P, Mihich E, Ehrke MJ. Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin. International Journal of Cancer. 59: 83-93. PMID 7927909 DOI: 10.1002/Ijc.2910590117 |
0.328 |
|
| 1993 |
Verstovsek S, Maccubbin DL, Ehrke MJ, Mihich E. Polymyxin B-mediated lysis of tumor cells. International Archives of Allergy and Immunology. 100: 47-52. PMID 8428163 DOI: 10.1159/000236386 |
0.347 |
|
| 1993 |
Ho RL, Maccubbin DL, Ujházy P, Zaleskis G, Eppolito C, Mihich E, Ehrke MJ. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma. Oncology Research. 5: 363-72. PMID 8038457 |
0.346 |
|
| 1992 |
Verstovsek S, Maccubbin D, Ehrke MJ, Mihich E. Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. Cancer Research. 52: 3880-5. PMID 1617664 |
0.327 |
|
| 1989 |
Maccubbin DL, Mace KF, Ehrke MJ, Mihich E. Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Research. 49: 4216-24. PMID 2525950 |
0.332 |
|
| 1988 |
Mace KF, Ehrke MJ, Hori K, Maccubbin DL, Mihich E. Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Research. 48: 5427-32. PMID 3416299 |
0.301 |
|
| 1988 |
Ehrke MJ, Ho RL, Hori K. Species-specific TNF induction of thymocyte proliferation. Cancer Immunology, Immunotherapy : Cii. 27: 103-8. PMID 3262011 |
0.355 |
|
| 1987 |
Hori K, Ehrke MJ, Mace K, Mihich E. Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and gamma-interferon. Cancer Research. 47: 5868-74. PMID 3117358 |
0.362 |
|
| 1987 |
Hori K, Ehrke MJ, Mace K, Maccubbin D, Doyle MJ, Otsuka Y, Mihich E. Effect of recombinant human tumor necrosis factor on the induction of murine macrophage tumoricidal activity. Cancer Research. 47: 2793-8. PMID 2882835 |
0.364 |
|
| Show low-probability matches. |